Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, 16-Week Phase II Study to Evaluate Efficacy and Safety of RDEA3170 5 mg, 10 mg, and 12.5 mg Versus Placebo and Open-Label Allopurinol 200 mg as a Reference Arm in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Next Previous
Trial Profile

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, 16-Week Phase II Study to Evaluate Efficacy and Safety of RDEA3170 5 mg, 10 mg, and 12.5 mg Versus Placebo and Open-Label Allopurinol 200 mg as a Reference Arm in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verinurad (Primary) ; Allopurinol
  • Indications Gout; Hyperuricaemia
  • Focus Therapeutic Use
  • Sponsors Ardea Biosciences; AstraZeneca

Most Recent Events

  • 25 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
  • 24 Sep 2014 Planned number of patients changed from 280 to 200 as reported by ClinicalTrials.gov record.
  • 24 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top